taspoglutide
Peptideexperimental
Taspoglutide is a former experimental drug, a glucagon-like peptide-1 agonist, that was under investigation for treatment of type 2 diabetes and being codeveloped by Ipsen and Roche. — Wikipedia
Clinical trial activity
13 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
12
Phase 3
10
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00423501)
Timeline
Indications
Studied for
Mechanism of action
GLP1R agonist
Peptide, GLP-1 analogue. Development stopped due to adverse events.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTaspoglutide ↗
- ChEMBLCHEMBL2107860 ↗
Also known as
- bim51077
- bim 51077
- bim-51077
- bim-51077
- bim-51077
- bim51079
- bim 51079
- bim-51079
- bim51182
- bim 51182
- bim-51182
- itm077
- itm 077
- itm-077
- r 1583
- r-1583
- r1583 cpd
- ro-5073031
- ro-5073031
- taspoglutide
- taspoglutide
- taspoglutide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01051011 | Phase 3 | Jan 1, 2010 | Roche |
| NCT01018173 | Phase 3 | Jan 1, 2010 | Roche |
| NCT00909597 | Phase 3 | May 1, 2009 | Roche |
| NCT00823992 | Phase 3 | Jan 1, 2009 | Roche |
| NCT00809705 | Phase 3 | Dec 1, 2008 | Roche |
| NCT00755287 | Phase 3 | Nov 1, 2008 | Roche |
| NCT00811460 | Phase 1 | Nov 1, 2008 | Roche |
| NCT00754988 | Phase 3 | Oct 1, 2008 | Roche |
| NCT00744367 | Phase 3 | Oct 1, 2008 | Roche |
| NCT00744926 | Phase 3 | Aug 1, 2008 | Roche |
| NCT00717457 | Phase 3 | Jul 1, 2008 | Roche |
| NCT00460941 | Phase 2 | Apr 1, 2007 | Roche |
| NCT00423501 | Phase 2 | Feb 1, 2007 | Roche |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 13 | 13 | 3 | 2007 |
1 organizations
Page 1 / 1